HeartBeam Inc. (NASDAQ: BEAT) is tackling one of the most persistent challenges in cardiac care: patient delay in seeking treatment. Cardiovascular disease remains the leading cause of death in the United States, accounting for more than 919,000 deaths in 2023, or roughly one in every five deaths, according to the Centers for Disease Control and Prevention. The company's HeartBeam System aims to transform how ECG data are collected and used, potentially enabling earlier detection and intervention.
The scale and severity of cardiac disease underscore the urgency of new approaches. Aging populations, lifestyle factors, and persistent gaps in early detection continue to challenge healthcare systems globally. HeartBeam is positioning its solutions at the intersection of rising clinical need and evolving innovation. By improving how cardiac conditions are identified and monitored, the company hopes to address the critical gap between symptom onset and medical care.
For more information on HeartBeam and its latest developments, visit the company's newsroom at https://ibn.fm/BEAT.
Note to Investors: The latest news and updates relating to BEAT are available in the company's newsroom. MissionIR, a specialized communications platform, assists with syndicated content to enhance visibility for private and public companies. MissionIR is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN to millions of followers, and a full array of tailored corporate communications solutions.
With broad reach and a seasoned team of contributing journalists and writers, MissionIR is uniquely positioned to serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today's market, MissionIR brings its clients unparalleled recognition and brand awareness.
For more information, visit www.MissionIR.com. Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer.
